Published in AIDS Weekly, March 21st, 2005
According to researchers in the United States, "In 2004, visceral leishmaniasis (kala-azar) maintains its status as a neglected, if not 'most neglected' disease.
"Lack of affordable new drugs, still a basic unsolved problem, has also been joined by additional therapeutic obstacles including large-scale resistance to pentavalent antimony (Sb) in India and coinfection with human immunodeficiency virus in all endemic regions."
"Nevertheless," said H.W. Murray and colleagues, "available treatment options have actually expanded because the energetic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.